x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Dr. Chapa’s OBGYN Clinical Pearls

Dr. Chapa’s Clinical Pearls

Relevant, evidence based, and practical information for medical students, residents, and practicing healthcare providers regarding all things women’s healthcare! This podcast is intended to be clinically relevant, engaging, and FUN, because medical education should NOT be boring! Welcome...to Clinical Pearls.

science

All Episodes

00:32:02

The “Broken” IUD: Detection and Clinical Management

Dr. Chapa’s OBGYN Clinical Pearls ·

2024/08/22

The IUD is a very safe and supremely effective contraceptive method. Given its increasing rate of use, practitioners are bound to see its relatively infrequent complications with greater regularity. Typical complications are considered “lost strings“, uterine perforation at placement, and expulsion. But there is another complication, device FRACTURE at removal. This can cause distress to the patient and can lead to additional interventions. Fracture of an intrauterine device (IUD) upon removal is a

en

00:46:16

Umbilical Cord Gases: What, Why, When?

Dr. Chapa’s OBGYN Clinical Pearls ·

2024/08/21

In 1958, James et al. first described umbilical cord blood gas analysis to evaluate the fetus's metabolic condition at the time of delivery. It's recommended by both the British and American Colleges of Obstetrics and Gynecology for all high-risk deliveries. Cord blood gas provides the most accurate and objective evidence of fetal acidosis at the time of birth. Still, there is no universal agreement on when to perform umbilical artery gas analysis, or cord gas, for babies. Some suggest that

en

00:22:15

FDA HPV Self-Swab Ready Aug 15, '24: NOT FOR HOME...

Dr. Chapa’s OBGYN Clinical Pearls ·

2024/08/18

According to the National Institutes of Health, almost 13,000 women in the United States are diagnosed with cervical cancer each year, resulting in around 4,000 deaths, with most of the deaths occurring among under-screened women. Now, there is potentially a barrier-breaker. As of August 15, 2024, self-collection kits for cervical cancer screening may be available in doctor's offices and other clinical sites, ready for use. The kits allow patients to collect their own vaginal sample for HPV

en

00:32:30

NEW Syphilis At-Home Test: Promises and Problems

Dr. Chapa’s OBGYN Clinical Pearls ·

2024/08/18

The rise of home testing for STIs/HIV started long before the recent pandemic (the FDA approved its first HIV home test collection kit way back in 1996), but COVID-19 seems to have accelerated the popularity of getting tested from the comfort of our homes. In Nov 2023, the Food and Drug Administration granted marketing authorization, the first of its kind, for an at-home test for chlamydia and gonorrhea. The test kit, called Simple 2, is available online through various offerings. Chlamydia and

en

00:41:32

2024 UPDATE: Mpox in Pregnancy

Dr. Chapa’s OBGYN Clinical Pearls ·

2024/08/16

The World Health Organization declared on 8/14/24 that the increasing spread of Mpox in Africa is a global health emergency, warning the virus might ultimately spill across international borders. Mpox, also known as monkeypox, was first identified by scientists in 1958 when there were outbreaks of a “pox-like” disease in monkeys. Until recently, most human cases were seen in people in central and West Africa who had close contact with infected animals. In 2022, the virus was confirmed to spread via

en

00:43:18

Boar’s Head, Listeria, and Pregnancy

Dr. Chapa’s OBGYN Clinical Pearls ·

2024/08/13

On July 26, 2024, Boar’s Head issued its recall of 7 million pounds of ready-to-eat meat and poultry products that might be contaminated with the potential harmful bacteria, listeria. Sporadic listeria outbreaks are nothing new; in June 2024, chicken-based products were recalled for the same concern in Canada. The US recall includes more than 70 products — including liverwurst, ham, beef salami and bologna. Listeriosis is reportable to the local health department of the county in which the patient

en

00:35:23

New Way to Reduce HDFN?: Enter, Nipocalimab

Dr. Chapa’s OBGYN Clinical Pearls ·

2024/08/12

Our tagline, “Medicine moves fast“, is the absolute truth! Historically, identification of fetuses at risk of hemolytic disease of the fetus/newborn (HDFN) required amniocentesis for determination of the Delta OD450, Liley Curve. This was the first screen, which would then trigger cordocentesis for determination of the fetal hematocrit. We’ve now moved on to middle cerebral artery (MCA) doppler of the fetus for identification of those at risk. Additionally, we now have an ability to ascertain

en

00:39:51

The Return to LT-O-Whole Blood (LTOWB) for OB...

Dr. Chapa’s OBGYN Clinical Pearls ·

2024/08/09

Prior to the 1970s, when component therapy became the preferred method of resuscitation, whole blood (WB) was the resuscitative medium of choice for hemorrhagic shock. In modern medicine, sometimes it turns out that the old way is better than the new…and using whole blood for transfusions is one example. Research is emerging that shows whole blood works better for these patients than fractionated components of blood. Beginning in 2017, multiple stakeholders within the Southwest Texas Regional

en

00:51:05

2024 CDC MEC UPDATE! HOT OFF THE PRESS!

Dr. Chapa’s OBGYN Clinical Pearls ·

2024/08/08

MEC CHANGES ARE HERE! During January 2022, the CDC held virtual scoping meetings that included 27 participants with expertise in contraception, adolescent health, and thrombosis, as well as representatives from partner organizations, to solicit their individual input on the scope for updating both the 2016 U.S. MEC. The 27 invited participants represented various types of health care providers and health care provider organizations. This led to a subsequent expert meeting held during January 2023

en

00:24:04

New Non-Estrogen Medication for Hot Flashes? Veozah's...

Dr. Chapa’s OBGYN Clinical Pearls ·

2024/08/03

In May 2023, the FDA approved fezolinetant (Veozah), an oral medication that's the first neurokinin 3 (NK3) receptor antagonist to treat moderate to severe hot flashes caused by menopause. Now, a separate oral medication which blocks the NK 1 and 3 receptor iis on the scene. Although not yet FDA approved, the published phase 1, 2, and 3 data make this approval very likely. Bayer, the manufacturer of elinzanetant, has just submitted a New Drug Application for its approval. In this episode, we

en

00:35:37

Antepartum AI for Stillbirth Prevention

Dr. Chapa’s OBGYN Clinical Pearls ·

2024/08/02

Artificial Intelligence (AI) has arrived. Machine Learningis a form of AI which is being investigated/used for improving maternal outcomes. The UK has already launched the TOMMY APP (through the RCOG) for use to reduce PTB and stillbirths in the UK. In this episode we will highlight a new systematic review which assessed Machine Learning’s ability to predict stillbirth. Did this work? This is a hot topic, especially since the passage of the Maternal and Child Stillbirth Prevention Act here in the

en

00:33:54

Maternal Obesity and SUID: New Data

Dr. Chapa’s OBGYN Clinical Pearls ·

2024/07/30

We all are aware that multiple adverse obstetrical outcomes have been linked to maternal obesity, such as stillbirth, preterm birth, NICUs admission, and congenital anomalies. But once delivery and hospital discharge occurs uneventfully, a new cohort study is raising the alarm for another possible adverse event up until the child’s first year of life: Sudden Unexpected Infant Death (SUID). SUID is devastating. In this episode we will review this new publication, which is making medical headlines

en

00:16:56

NEW Clinical Practice Update (Aug 2024)

Dr. Chapa’s OBGYN Clinical Pearls ·

2024/07/29

Our immediate past episode summarized a validation study of cell-free DNA (cfDNA) isolated from maternal plasma for fetal RBC genotyping in alloimmunized patients. And now, in this episode, we will highlight a BRAND NEW ACOG Clinical Practice Update on this very subject! YEP... we now have new ACOG guidance regarding using maternal derived cfDNA for fetal RBC antigen detection as an option for care in alloimmunized pregnancies. This is how "medicine moves fast"! Listen in for details

en

00:23:19

cfDNA Fetal RBC Genotyping in Alloimmunized...

Dr. Chapa’s OBGYN Clinical Pearls ·

2024/07/27

In September 2022, a cell-free DNA assay using next-generation sequencing and quantitative counting tech for fetal antigen status determination became clinically available in the USA. This allowed maternal screening for fetal RBC genotypes for RH negative patients. This test was recognized by thre ACOG in March 2024 as one option to “triage” anti-D immunoglobulin in RH negative women. But can this technology be trusted in alloimmunized patients? In women with antibodies against foreign antibodies,

en

00:45:15

Skyrocketing Sex Strangulation Rates: The Alert

Dr. Chapa’s OBGYN Clinical Pearls ·

2024/07/26

First off, let’s all agree that everyone has a different STYLE of sexual intimacy, and that’s OK. Yep, we all understand that there's always been a lot of sexual act “diversity” in the world… and throughout history. But there is a more recent trend that has increased in popularity, some surveys attribute it to its representation in pornography, that may be dangerous. This was in recent print as of July 3, 2024! This is "sexual choking”. But this term is not accurate because it actually is a

en

00:38:50

Candida as IAI & Perinatal Sepsis? YES.

Dr. Chapa’s OBGYN Clinical Pearls ·

2024/07/24

Candida in women is being right? Afterall, vulvovaginal candidiasis during pregnancy is common. Candida species may be isolated from the vagina of 15 %-21% of nonpregnant women; this rate increases to 30% during pregnancy. While it is generally benign and isolated to the vagina clinically, some Candida species have the capacity to be troublemakers. C. Glabrata has the potential to be a bad player, with the possibility of invasive disease. Candida IAI is rare but can lead to neonatal infection, high

en

00:41:05

The New PreTRM Biomarker Test

Dr. Chapa’s OBGYN Clinical Pearls ·

2024/07/22

Biomarker testing has arrived in Obstetrics. Of course, we have been using some biomarkers for years, like PAMG1 (Amnisure) and AFP+ILGFBP1 (ROM Plus) for ROM evaluation. In May 2023, the FDA cleared Thermo Fisher Scientific's maternal serum biomarker test for prediction of preeclampsia with severe features in hospitalized patients (and we have a prior episode on that). Now, as of July 9, 2024, published data has arrived for a new maternal serum biomarker ratio for the prediction of preterm

en

00:45:52

Sequential CX Ripening: Which Should Be First?

Dr. Chapa’s OBGYN Clinical Pearls ·

2024/07/21

Published studies, including 2 large network meta-analyses, support the safety and efficacy of misoprostol (PG E1) when used for cervical ripening and labor induction. Based on cumulative data, misoprostol administered vaginally at doses of 50 μg has the highest probability of achieving vaginal delivery within 24 hours. Prostaglandin E2 also has proven efficacy. Plus, we are all aware of the safety and efficacy of mechanical methods of cervical ripening; yes…we know that these options may be used

en

00:40:08

Latent TB Treatment in OB

Dr. Chapa’s OBGYN Clinical Pearls ·

2024/07/19

Tuberculosis (TB) was historically called "consumption" due to the dramatic weight loss and wasting away experienced by patients. The modern name "tuberculosis" was first published by J. L. Schönlein in 1832. Today, between 3% and 5% of the U.S. population are estimated to be living with latent TB infection. Contrast that with the worldwide statistics which state that nearly one fourth of the world population has TB infection. In some countries in sub-Saharan Africa and Asia, the

en

00:51:46

Previable and Periviable PPROM (NEW SMFM CS #71)

Dr. Chapa’s OBGYN Clinical Pearls ·

2024/07/17

Approximately 0.5% of all births occur before the 3rd trimester of pregnancy, and very early deliveries result in the majority of neonatal deaths and more than 40% of infant deaths. Preterm prelabor rupture of membranes (PPROM) is a known risk factor for preterm birth and is responsible for 30–40% of preterm deliveries. While PROM occurs around 8% of all (term) pregnancies, PPROM occurs around 1% of the time. Periviable birth is delivery occurring from 20 0/7 weeks to 25 6/7 weeks of gestation

en

1,071 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter